ProBio signs global antibody licensing deal with AbTis
The asset was developed via ProBio's biologics discovery and development operations and is directed against an oncology target.
Drug Development
Lilly-backed Oyster Therapeutics raises $60m for neurological degraders
Delix Therapeutics raises $100m for zalsupindole development
Charles River agrees $470m deal for Frontage assets
Network Bio partners with Duke University on AI disease models
Bio-Thera gains Chinese approval for spondylitis and rheumatoid arthritis drug
Armada to combine with Brains Bioceutical in $750m deal
Alfasigma receives EC’s expanded approval for filgotinib to treat axSpA
